Parvovirus B19 transmission by heat-treated clotting factor concentrates. - Wikidata - wikimedia - TriplyDB

Parvovirus B19 transmission by heat-treated clotting factor concentrates.

Parvovirus B19 transmission by heat-treated clotting factor concentrates.

http://www.wikidata.org/entity/Q45856193

about

Transfusion-transmitted infections Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies.Characterization of Parvovirus B19 genotype 2 in KU812Ep6 cells.Cross-border paid plasma donation among injection drug users in two Mexico-U.S. border cities.Parvovirus B19 - Revised.Human erythrovirus B19 and blood transfusion - an update.Serological study on parvovirus B19 infection in multitransfused thalassemia major patients and its transmission through donor units.Stable Expression of Recombinant Factor VIII in CHO Cells Using Methotrexate-Driven Transgene Amplification.Parvovirus B19 Passive Transmission by Transfusion of Intercept® Blood System-Treated Platelet Concentrate A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion.Identification and characterization of persistent human erythrovirus infection in blood donor samples.Parvovirus b19 infections and blood counts in blood donors.Human parvovirus B19 in patients with beta thalassemia major from Tehran, Iran.Blood Clotting Factor VIII: From Evolution to Therapy.Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease.Human Parvoviruses.Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates.Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses.Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests.Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples.Nuclease-resistant single-stranded DNA controls for nucleic acid amplification assays.Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates.Recipients potentially infected with parvovirus B19 by red blood cell products.Inactivation and neutralization of parvovirus B19 Genotype 3.Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.Multicenter evaluation of a commercial multiplex polymerase chain reaction test for screening plasma donations for parvovirus B19 DNA and hepatitis A virus RNA.Effects of varying virus-spiking conditions on a virus-removal filter Planova™ 20N in a virus validation study of antibody solutions.Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.Different susceptibility of B19 virus and mice minute virus to low pH treatment.Effects of transfusion on human erythrovirus B19-susceptible or -infected pediatric recipients in a genotype 3-endemic area.Parvovirus B19 transmission by a high-purity factor VIII concentrate.Impact of chemiluminescent enzyme immunoassay screening for human parvovirus B19 antigen in Japanese blood donors.Symptomatic parvovirus B19 infection caused by blood component transfusion.

P2860

Q27480405-EF9623B4-8C56-4E67-9DFF-45F000529ADF Q33735132-E1C676E2-B1D8-40C1-999D-DCA4389914A9 Q34039466-B265D58E-6C73-4A3B-B164-2959F7C4565D Q34124006-F3A09867-AE99-46F6-BD4D-5BD18A542A81 Q34202259-CE83E72A-2C10-4043-877B-1462B20C26CD Q34625443-2E0407F3-4802-406C-BC9E-1989B4136557 Q34660084-1D6A17C1-249D-4887-AADE-24C0105CD4F8 Q35174034-BEDE0E02-CB43-4B4A-B634-E48799F41250 Q36025976-C1E4B3A8-EFFE-4354-99C7-B4876A7B8ECF Q37045818-7D20D203-B4E7-430B-B138-31D7E29E1A0F Q37398336-834D357B-B1EC-4B62-9921-D3DCF4462E94 Q37596753-88C7E0FF-9C28-4C4A-BFA8-E8707A57B912 Q37630327-AF85FC35-F4FE-4506-9802-E54AE664E53B Q37740416-EC65BD64-2C16-4C12-B75C-2A5E3C608580 Q38118763-81A0D457-69E0-472E-9B87-37687B61C576 Q38151843-0BFE1CBD-0D3B-431E-8169-6525D16E10C0 Q38661867-D30C54E3-5E07-46FA-B498-ADB22C76DAAC Q38996997-BC140C96-797F-4B7F-A804-8A878B722232 Q39992302-71EB78C6-BD6B-4D79-93BA-8858E54B3492 Q40078515-CF3A1C2B-7091-4CCB-8F6C-BC57C6C03402 Q40834278-7A1497C0-6FE1-4536-9542-B2254D9633CD Q41294587-7D1F2D73-439E-475D-A885-A15345A3E12F Q42413043-50C8B957-2F15-4629-9D84-AACBD4F3DA78 Q43461065-5A0CECCE-2BA3-4B7C-BE2A-077ABEAFF107 Q44099707-6B6BF147-1CC0-453A-947A-0D7894713655 Q44659453-259E64FB-780F-44F5-A246-C65402CF86F2 Q44807693-9763A415-A2C2-4EEA-832A-34275B22993A Q45357632-2C3D658A-4EB2-4682-93BB-C20A0F5A6C7D Q45369186-E4C9A137-CD54-4791-A1EF-2EB13F75650B Q45410532-733703A6-60C8-49C0-B9AD-A818C535D67C Q45620572-C0EEA94A-D295-4458-B961-72C46AD79B29 Q46428631-5864EBF3-FE78-44EE-B2A3-2C47CB36EAB1 Q47786736-CEF9448F-CE06-4AB9-B0B4-A908DA143D36 Q50500602-6C41EEB2-299C-49D1-85B3-D8B789ADB537 Q50545205-752A02F2-5DDD-45C6-8254-0A74D5E07631

P2860

Parvovirus B19 transmission by heat-treated clotting factor concentrates.

http://www.wikidata.org/entity/Q45856193

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Parvovirus B19 transmission by heat-treated clotting factor concentrates.

@en

Parvovirus B19 transmission by heat-treated clotting factor concentrates.

@nl

type

label

Parvovirus B19 transmission by heat-treated clotting factor concentrates.

@en

Parvovirus B19 transmission by heat-treated clotting factor concentrates.

@nl

prefLabel

Parvovirus B19 transmission by heat-treated clotting factor concentrates.

@en

Parvovirus B19 transmission by heat-treated clotting factor concentrates.

@nl

P1433

Q45856193-F10981F2-BE48-4689-B53C-D0BDC190574D

P1476

Q45856193-F9005980-FCD4-42EB-9751-29DF6B1706CC

P2093

Q45856193-180FC12B-2193-41E8-9BF1-A3D43C7BFC42

Q45856193-392F3FFA-2088-473D-A7AD-D7A2AB0A38F2

Q45856193-3E3885E8-2ED3-43CB-9321-5C2EC5443933

Q45856193-593D0D9D-C512-4FE7-85DD-2239DBFD7382

Q45856193-71EC09C9-0C5B-445C-8CF9-98F07F630AA2

Q45856193-CD18E8D9-A5F8-4E85-BF57-DEFCC21FA203

Q45856193-D88F2DCF-A2A5-4034-8B46-0A830437D6F6

Q45856193-F8C7672A-3BB9-4E8B-B2B6-9905A64200EF

P2860

Q45856193-11F84ACE-E5B2-4D43-9D00-412E8FF8DCB5

Q45856193-22EBA05B-A4B7-4B7E-9B52-F2E9E58B61A8

Q45856193-2F7824E0-9BFE-4CCD-8912-FF99570F71E1

Q45856193-3D22C58D-9D9A-46C5-8E25-AFEDC4B11F77

Q45856193-4C356DF1-0820-4F21-8E80-7DD0C0BC84CF

Q45856193-4F737ED9-C82D-4A49-B019-54A2B3AD2DAE

Q45856193-4F8E45F5-FC88-48F0-BF08-BCD444D09DD2

Q45856193-85F0598B-924A-4080-BC8E-7D86DA2C5A85

Q45856193-882A52F8-5017-4B65-9A7E-E0B615E89D02

Q45856193-CA203AB5-7D4C-4A43-A0A0-7561412E9754

P304

Q45856193-93618777-4631-4727-A7D9-8A2A2ADC98F4

P31

Q45856193-C0189E23-11A9-449E-BDC0-86E55E5E47B7

P356

Q45856193-5F124F36-310F-40FA-BEB6-B2A626DE427E

P433

Q45856193-72C6817D-56AC-4926-93B4-572E42FC30EA

P478

Q45856193-0F8C4775-60CC-40AF-9091-34D94C081D85

P577

Q45856193-EECEB438-0AA5-49D5-9CD9-0F97A03AD433

P698

Q45856193-7E901707-D141-4FC3-8CDB-C8D8976AA909

P356

J.1537-2995.2002.00221.X

P1433

P1476

Parvovirus B19 transmission by heat-treated clotting factor concentrates.

@en

P2093

Anna Maria Eis-Hübinger

http://www.w3.org/2001/XMLSchema#string

Hannelore Willkommen

http://www.w3.org/2001/XMLSchema#string

Hans Herrmann Brackmann

http://www.w3.org/2001/XMLSchema#string

Holger Seitz

http://www.w3.org/2001/XMLSchema#string

Ivo Schmidt

http://www.w3.org/2001/XMLSchema#string

Johannes Blümel

http://www.w3.org/2001/XMLSchema#string

Johannes Löwer

http://www.w3.org/2001/XMLSchema#string

Wolfgang Effenberger

http://www.w3.org/2001/XMLSchema#string

P2860

Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying disease.

Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review.

[Severe parvovirus B19 infection in an immunocompetent child with hemophilia A]

Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity.

Experimental parvoviral infection in humans.

The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability.

Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation.

Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.

Eliminating parvovirus B19 from blood products.

Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.

P304

1473-1481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1537-2995.2002.00221.X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12421221

http://www.w3.org/2001/XMLSchema#string